Concomitant chemoradiotherapy with cisplatin, 5‐fluorouracil and hydroxyurea in poor‐prognosis head and neck cancer
Authors:
Open Access
- 1 June 1992
- journal article
- Published by Wiley in The Laryngoscope
- Vol. 102 (6) , 630-636
Abstract
Based on encouraging results with 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy in patients with advanced or recurrent head and neck cancer, an attempt was made to modulate the regimen by the addition of cisplatin as a third active agent. A cohort of 26 patients with head and neck cancer of all histologies were entered into a broad phase I study investigating simultaneous radiation therapy, 5-FU (with or without leucovorin), HU, and infusional cisplatin administered on an alternate-week schedule. Eleven patients (group 1) had failed prior curative local therapy and 15 patients (group 2) were considered to have a poor prognosis with standard therapy. The median follow-up was 30 months. The response rate for all evaluable patients was 82% (14/17), and the complete response rate was 65% (11/17). Patients in group 1 demonstrated a high failure rate (9/11), while few group 2 patients failed after treatment (2/15). The median time to progression was 4.4 months in group 1 and has not been reached in group 2. Patients in group 1 failed locally (7/11), while no local failures were observed in group 2. Acute and cumulative hematologic toxicity was encountered at all dose levels and schedules tested and prevented escalation of the cisplatin dose beyond the desired level of 100 mg/m2 per month. Mucositis was a second significant toxicity in patients with head and neck cancer and was more pronounced during cycles containing leucovorin. A detailed analysis of survival, time to progression, and site of failure is presented.Keywords
This publication has 18 references indexed in Scilit:
- Survival and Analysis of Failure Following Hydroxyurea, 5-Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck CancerAmerican Journal of Clinical Oncology, 1991
- Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repairCancer Chemotherapy and Pharmacology, 1989
- Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.Proceedings of the National Academy of Sciences, 1986
- Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer.Journal of Clinical Oncology, 1986
- Hydroxyurea: A radiation potentiator in carcinoma of the uterine cervixAmerican Journal of Obstetrics and Gynecology, 1983
- Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesisBiochemical Pharmacology, 1982
- A Phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomasJournal of Neurosurgery, 1979
- Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized studyAmerican Journal of Roentgenology, 1976
- Fluorinated pyrimidines. Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotidesBiochemistry, 1974
- Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylateBiochemistry, 1974